Humacyte, Inc. announced a new U.S. patent covering key methods in the manufacturing, sterilization, storage, and shipping of its bioengineered tissue product Symvess, extending intellectual property protection until 2043. This patent strengthens Humacyte's portfolio and supports the commercial scale production of Symvess, which is FDA-approved for vascular trauma and under review for dialysis access. The protection enhances the company's ability to advance regenerative medicine products and expand clinical applications. Humacyte operates a large bioprocessing facility in North Carolina and continues development in multiple vascular and tissue applications.
Humacyte's recent patent issuance comes as a backdrop for the health sector's market activity on Pluang. For readers following the health sector, here is Pluang's market snapshot as of Oct 28, 2026 19:11 WIB: out of 150 priced US health stocks, 42 rose and 97 fell. Notable movers include GEHC at USD 77.00 with an 8.28% increase, BNGO at USD 1.12 down 8.20% with a typical hold time of 51 days, and ACB at USD 4.44 up 6.99% with a typical hold time of 26 days.
Arcutis Biotherapeutics has appointed Dr. Rob Scott, a seasoned pharmaceutical executive with over 40 years of experience, to its Board of Directors. Dr. Scott's expertise in developing and securing approvals for innovative medicines, including derma...
Air Canada and CAE announced the opening of applications on November 1, 2026, for the 2027 Commandante-Judy-Cameron scholarships. These scholarships support up to eight Canadian women pursuing professional pilot or aircraft maintenance technician tra...
The Legacy Lab by Team One released its 2026 Legacy Makers 100 list, identifying brands consumers trust to have their best interests at heart and remain relevant long-term. St. Jude Children's Research Hospital topped the list for the second year. Th...
Circuit Mind has introduced AVE (Agentic Verification Engine), an AI-powered application that verifies printed circuit board (PCB) schematics against datasheets and internal design rules to catch errors early and avoid expensive respins. AVE compleme...
Grabar Law Office is investigating claims against officers and directors of Erasca, Planet Fitness, PROCEPT BioRobotics, and The Simply Good Foods Company for alleged breaches of fiduciary duties. The investigations focus on misleading statements and...
